Iris Wieser1, Chee Won Oh2, Rakhshandra Talpur2, Madeleine Duvic2. 1. Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas; Department of Dermatology, Paracelsus Medical University, Salzburg, Austria. Electronic address: iris.wieser@hotmail.com. 2. Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Lymphomatoid papulosis (LyP) is a CD30(+) lymphoproliferative disorder, with a self-regressing clinical course and malignant histopathology. OBJECTIVE: The aim of this study was to evaluate characteristics, risk factors, associated malignancies, long-term outcome, and treatment of LyP in a large cohort representing the experience of the MD Anderson Cancer Center. METHODS: Patient charts and clinical and histopathologic data of 180 patients with LyP were retrospectively assessed. RESULTS: A total of 56.7% of patients was men. Histologic subtype A was found in 47.2%, type B in 17.2%, type C in 22.8%, type D in 7.8%, type E in 0.6%, and mixed subtype in 4.4% of the patients. One hundred fourteen lymphomas were observed in 93 patients, with mycosis fungoides (61.4%) and anaplastic large cell lymphoma (26.3%) being the most common forms. Risk factors for development of lymphoma included sex and histologic subtype. Number of lesions and symptom severity were not associated with lymphoma development. Patients with type D were less likely to have lymphomas. Treatment provided symptomatic relief but did not prevent progression to lymphoma. LIMITATIONS: The limitation of this study is the retrospective study design. CONCLUSION: Patients with LyP are at increased risk of associated lymphomas. Thorough patient counseling is needed and long follow-up periods are required to detect and treat secondary lymphomas.
BACKGROUND:Lymphomatoid papulosis (LyP) is a CD30(+) lymphoproliferative disorder, with a self-regressing clinical course and malignant histopathology. OBJECTIVE: The aim of this study was to evaluate characteristics, risk factors, associated malignancies, long-term outcome, and treatment of LyP in a large cohort representing the experience of the MD Anderson Cancer Center. METHODS:Patient charts and clinical and histopathologic data of 180 patients with LyP were retrospectively assessed. RESULTS: A total of 56.7% of patients was men. Histologic subtype A was found in 47.2%, type B in 17.2%, type C in 22.8%, type D in 7.8%, type E in 0.6%, and mixed subtype in 4.4% of the patients. One hundred fourteen lymphomas were observed in 93 patients, with mycosis fungoides (61.4%) and anaplastic large cell lymphoma (26.3%) being the most common forms. Risk factors for development of lymphoma included sex and histologic subtype. Number of lesions and symptom severity were not associated with lymphoma development. Patients with type D were less likely to have lymphomas. Treatment provided symptomatic relief but did not prevent progression to lymphoma. LIMITATIONS: The limitation of this study is the retrospective study design. CONCLUSION:Patients with LyP are at increased risk of associated lymphomas. Thorough patient counseling is needed and long follow-up periods are required to detect and treat secondary lymphomas.
Authors: Thomas Menter; Veronika Ballova; Clemens Caspar; Thomas Wolff; Benjamin Kasenda; Gad Singer; Darius Juskevicius; Alexandar Tzankov; Stefan Dirnhofer Journal: Virchows Arch Date: 2019-01-26 Impact factor: 4.064
Authors: Alejandro A Gru; Carlos E Bacchi; Melissa Pulitzer; Govind Bhagat; Werner Kempf; Alistair Robson; Jose A Plaza; Laura Pincus; Shyam Raghavan; Mina Xu; Tiago Vencato da Silva; Andrea L Salavaggione; Antonio Subtil; Maxime Battistella Journal: J Cutan Pathol Date: 2021-07-05 Impact factor: 1.458
Authors: Subuhi Kaul; Micah Belzberg; John-Douglas Matthew Hughes; Varun Mahadevan; Raveena Khanna; Pegah R Bakhshi; Michael S Hong; Kyle A Williams; Annie L Grossberg; Shawn G Kwatra; Ronald J Sweren Journal: Medicines (Basel) Date: 2019-12-26